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Abstract
Background: Recent research has indicated that short term administration of glycine propionyl-
L-carnitine (GPLC) significantly elevates levels of nitric oxide metabolites at rest and in response
to reactive hyperaemia. However, no scientific evidence exists that suggests such supplementation
enhances exercise performance in healthy, trained individuals. The purpose of this study was to
examine the effects of GPLC on the performance of repeated high intensity stationary cycle sprints
with limited recovery periods in resistance trained male subjects.
Methods: In a double-blind, placebo-controlled, cross-over design, twenty-four male resistance
trained subjects (25.2 ± 3.6 years) participated in two test sessions separated by one week. Testing
was performed 90 minutes following oral ingestion of either 4.5 grams GPLC or 4.5 grams cellulose
(PL), in randomized order. The exercise testing protocol consisted of five 10-second Wingate cycle
sprints separated by 1-minute active recovery periods. Peak (PP) and mean values (MP) of sprint
power output and percent decrement of power (DEC) were determined per bout and
standardized relative to body masss. Heart rate (HR) and blood lactate (LAC) were measured prior
to, during and following the five sprint bouts.
Results: Significant main effects (p < 0.001) were observed for sprint bout order in values of PP,
MP, DEC, and HR. There were significant main effects detected for condition in PP and MP (p <
0.05), with values across the five sprint bouts 2.6 – 15% greater with GPLC. Significant statistical
interactions were detected between bout order and condition for both PP and MP (p < 0.05).
There was a significant main effect of condition for LAC, LAC values 15.7% lower 4 min post-
exercise with GPLC (p = 0.09) and with GPLC resulting in 16.2% less LAC at 14 min post-exercise
(p < 0.05).
Conclusion: These findings indicate that short-term oral supplementation of GPLC can enhance
peak power production in resistance trained males with significantly less LAC accumulation.
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Background
It is known that exercise hyperemia can provide a dra-
matic elevation of blood flow to specific active skeletal
musculature, which also corresponds to metabolic
demand [1]. There is an immediate and rapid increase in
flow in response to a single muscle contraction, and the
magnitude of the increased flow is directly related to the
intensity of the contraction [2]. During heavy exercise,
blood flow to local muscle tissue can be increased propor-
tionally with exercise intensity to levels 25 – 50 times of
those at rest [3]. This process is primarily a function of
vasodilation of the arterioles (distal, proximal, and feed)
and the pre-capillary sphincters, which is to a great degree
induced by factors such as adenosine, carbon dioxide, and
potassium, which are released in proportion to intensity
of effort by adjacent muscle fibers during exercise [4]. The
close coupling of muscular blood flow and exercise inten-
sity supports the theory that further elevations in localized
blood flow during exercise may, in some cases, result in
increased peak work capacity and/or increased resistance
to local muscle fatigue, thereby enhancing exercise per-
formance.
The process of vasodilation as a primary component of
exercise hyperemia involves mechanisms other than the
aforementioned muscle metabolite induced vasodilatory
mechanisms (adenosine, CO2, K+). For example, the ini-
tial increases of blood flow (first 1 – 2s) during exercise
are now believed to be related to increased concentrations
of acetylcholine as released by the motor end-plate during
muscle activation [5]. Tschakovsky and Joyner [6] out-
lined several mechanisms believed to contribute to the
secondary phase of vasodilation (3+ sec) including flow
mediated mechanisms, the mechanical muscle pump,
mechanically induced responses, muscle activation mech-
anisms, and red blood cell HbO2 desaturation mecha-
nisms. Each of these mechanisms can be associated with
different variations and intensities of exercise stresses.
However, each of these distinct mechanisms shares the
common function of initiating the synthesis of nitric
oxide (NO).
Nitric oxide (NO) is a very short-lived, reactive gaseous
nitrogen molecule that is involved in a variety of physio-
logical functions. Approximately twenty years ago, it was
revealed that NO was the endothelial factor responsible
for regulating muscle tone of vascular structures, origi-
nally referred to as endothelial dependent relaxation fac-
tor (EDRF) several years prior. However, a viable means to
manipulate this molecule has not been identified. There-
fore, it is uncertain at this time what influence increased
production of NO would have on cardiovascular func-
tioning and/or resistance to local muscle fatigue.
Nitric oxide is synthesized in endothelial cells from
arginine via enzymatic action of endothelium nitric oxide
synthase. This molecule diffuses easily into the vascular
smooth muscle where it binds to the enzyme guanylyl
cyclase, which in turn catalyzes the phosphorylation of
gunaosine-5-triphosphate (GTP) into cyclic gyanosine
monophosphate (cGMP). Cyclic GMP serves as an impor-
tant second messenger for many physiological functions,
including relaxation of smooth vascular muscle. The
amino acid, arginine, acts as a precursor to NO synthesis.
Due to this role, a significant nutritional supplement mar-
ket has developed for arginine-based products which sup-
posedly enhance the production of NO. However, the
current scientific evidence does not support the efficacy of
these products. To a great degree, the success of this mar-
keting has been based on evidence that direct infusion of
arginine has been shown to induce significant levels of
vasodilation [7], with enhanced hemodynamics [8] in
healthy persons. However, controlled investigations have
indicated that oral arginine supplementation did not have
any effect on 1) peripheral resistance or cardiac output
with a single 6 g dose [9] 2) endothelium-dependent
vasodilation with intake of 7 g daily for three days [10], or
3) endothelial function in healthy persons after 28 days
with 20 g arginine supplemented per day [11]. It has also
been shown that the arginine levels in healthy persons are
actually greater than what should theoretically be suffi-
cient to activate endothelial NOS and thereby produce
NO [12]. Thus, arginine based supplementation for
improved NO synthesis is without scientific basis.
An oral carnitine compound, glycine propionyl-L-carni-
tine (GPLC), has recently been shown by Bloomer and
associates to induce increased levels of plasma nitrates
and nitrites (NOx) at rest in sedentary persons [8]. The
same research group has also documented a dramatic ele-
vation in NOx levels at rest and in response to occlusive
hyperaemic testing in fifteen healthy resistance trained
men after seven days supplementation with 4 g GPLC
daily [13]. Following five minutes of upper arm occlusion
with isometric hand gripping, the NOx levels were
increased 16% and 17% over resting values with GPLC at
three and 10 minutes post-occlusion, respectively, com-
pared with 4% and 6% increases in NOx with placebo.
These early findings suggest potential applications in clin-
ical conditions or sports settings in which enhanced
blood flow would be beneficial. However, there has been
no examination of the effects of GPLC supplementation
on physiological functioning or sports performance in
exercise trained persons. Therefore, the present study was
performed to examine the effects of short-term GPLC sup-
plementation (4.5 g) on performance of repeated high-
intensity cycle sprints and consequential lactate accumu-
lation.Journal of the International Society of Sports Nutrition 2009, 6:9 http://www.jissn.com/content/6/1/9
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Methods
Research Participants
Thirty two male individuals volunteered to serve as
research participants for this investigation. Inclusion crite-
ria stipulated that all subjects were between the ages of 18
and 35 years and had participated in resistance training
activities at least twice per week over the six-month period
immediately prior to enrolment in this study. All testing
procedures were verbally explained in detail and subjects
provided written informed consent prior to participation,
in accordance with the guidelines established by the Insti-
tutional Medical Sciences Subcommittee for the Protec-
tion of Human Subjects.
Study Protocol
A double-blind, placebo-controlled, cross-over design was
utilized in this investigation. Research participants com-
pleted two testing sessions seven days apart using the
same testing protocol. Either GPLC or placebo (PL) was
administered orally 90 minutes prior to each test, in ran-
domized order. (See Supplementation Protocol Section).
Subjects were directed to continue the same general life-
style patterns of exercise and nutritional intake during
each seven-day period prior to the two exercise testing ses-
sions. To verify the consistency of training and diet, the
subjects were directed to complete a 7-day exercise log and
a 3-day dietary recall (two week days and one weekend
day) for each week prior to testing. The exercise log pro-
vided information regarding the volume (sets and reps) of
resistance training relative to upper body, lower body, or
total body structural movements. The dietary intake infor-
mation was analyzed using ESHA Food Processor SQL
dietary analysis software (ESHA Research, Salem, OR).
All research participants completed at least two familiari-
zation trials prior to participating in the two testing ses-
sions. The familiarization sessions followed the same
general protocol but without full measurements of the
actual exercise trials. On test days, participants were asked
to report to the testing laboratory in the morning follow-
ing a 12-hour period without food. They were also asked
to refrain from vigorous exercise in the 24-hour period
prior to testing. On arrival to the laboratory, the partici-
pants were provided with the respective supplement
assigned for that session (GPLC or PL) and began a 90
minute resting period prior to testing.
Supplementation Protocol
The two high intensity exercise trials were performed
under two conditions, one with GPLC and one without.
The study supplements (GPLC, PL) were provided by Jar-
row Formulas (Los Angeles, CA) in 750 mg capsules, with
six capsules equivalent to the 4.5 gram daily dose. The
GPLC was the USP grade nutritional product, GlycoCarn™
(Sigma Ta Health Sciences, S.p.A., Rome, Italy), which
consists of a molecular bonded form of glycine and propi-
onyl-L-carnitine. The dosage of GPLC applied in this
study is the same as that applied in previous research find-
ing elevated NOx levels at rest and in response to occlu-
sive hyperaemia [13]. The PL capsules were visually
identical and contained 750 mg of cellulose. The supple-
ment assignments were blinded to both the research par-
ticipants and the study investigators. Subjects ingested the
respective 4.5 gram supplement with 8 ounces of water
approximately 90 minutes prior to testing.
Testing Protocol
The assessment protocol consisted of five maximal effort
10-second cycle sprints performed with 1-minute active
recovery periods between bouts. While Wingate type test-
ing is typically performed using a single 30 second work
period, repeated 10 second sprints have been used when
testing exercise capacities similar to those required in rel-
atively intense exercise. The sprints were performed using
a Monarch 894E leg ergometer (Monarch, Varberb, Swe-
den) outfitted with pedal cages. The external resistance
applied was equivalent to 7.5% of each subject's body
mass. The testing protocol included a 10-minute warm-up
period cycling on the test bike at a pace of 60 RPM, with-
out external resistance. Following the warm-up period,
subjects were directed to gradually increase the pace of
their pedalling over several seconds until they reached a
maximal pace of unloaded sprinting. At this point, with a
verbal cadence, external resistance was applied thereby
initiating a 10-second period of sprint testing and data
collection. Verbal encouragement was provided by the
investigators to continue sprinting at maximal pace
throughout the 10-second bout. Subjects were directed to
continue pedalling at a slower controlled pace during the
1-minute active recovery periods. With five seconds
remaining in the recovery period, subjects were again
directed to gradually increase their pedalling to a sprinting
pace for the second sprint. This procedure was continued
for a total of five 10-second sprint bouts.
Anaerobic power output of the sprints was determined
using the SMI OptoSensor 2000 (Sports Medicine Indus-
tries, Inc., St. Cloud, Minn). Values of power output deter-
mined included peak power (PP) and mean power (MP)
which in this case were the average values of power output
during the first five seconds and total ten second period,
respectively. The third power output measure was a value
of power decrement (DEC) in which the difference in
power output between the first and second five second
periods are expressed as a percentage of the first.
Blood lactate levels were assessed using the Accutrend®
Lactate analyzer (Sports Resource Group, Inc., Pleas-
antville, NY). The analyzer was calibrated using the stand-
ard control solutions prior to each testing session. Lactate
values were determined at rest and post-exercise at min-Journal of the International Society of Sports Nutrition 2009, 6:9 http://www.jissn.com/content/6/1/9
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utes four and fourteen. Heart rate was measured using a
Polar HR monitor system with values assessed at rest, dur-
ing the final 5 seconds of each sprint as well as four and
fourteen minutes following completion of the fifth sprint.
Thigh girth was assessed using a Gulick tape with circum-
ferential measurements taken 15 mm superior to the
patella. Thigh girth was measured at rest and four minutes
following completion of the final sprint interval.
Statistics
Two-way repeated measures ANOVAs were used to deter-
mine whether there were statistically significant differ-
ences between conditions (GPLC, PL) and across time. In
the cases where significant main effects of condition or
condition × time interactions were detected, single degree
of freedom contrasts were used to determine condition
effects at each bout order without adjustment of the
acceptable level of significance. Net lactate accumulation
relative to the power output of the sprints was calculated
as the difference between the lactate measures at rest and
those at 14 min divided by the average of the five MP val-
ues. Relative total power decrement was calculated for PP
and MP as the relative difference between the first and last
bout of each test condition. Values were compared
between conditions with one-way ANOVA for repeated
measures. In all cases, p-values less than 0.05 were
accepted to determine statistical significance. All analyses
were performed using SPSS, Version 16.
Results
Participants
Twenty four of the 32 recruited subjects completed both
exercise trials. The study subjects were aged 25.2 ± 3.6
years with a mean body mass of 87.1 ± 14.5 kg and stature
of 177.8 ± 6.9 cm. The 24 study subjects were confirmed
to satisfy the inclusion criteria of consistent participation
in resistance training during the six months prior to this
study. Eight of the recruited subjects declined to partici-
pate in the research trial past the two familiarization test
sessions. The intense nature of this exercise protocol
appears to be related to the relatively high rate of attrition
(25%). All statistical analyses are based on the data col-
lected from the 24 subjects that completed both sprint test
sessions. Planned sample size (32) was based on an esti-
mated 10% dropout rate establishing a 0.75 level of
power with a 0.25 predicted effect size. The reduced
number of subjects limited statistical power to the 0.65
level, and is seen as a limitation of the present study as
potential differences between conditions may not have
been detected.
Lifestyle Records
Dietary log data
Macronutrient intake values for both study conditions are
presented in Table 1. Dietary intake data for protein (g),
carbohydrates (g), and fats (g) as well as total calories
were analyzed to determine daily averages which were
compared between study conditions. Analysis indicated
that there were no significant differences in these nutrient
values for the three-day period preceding each of the two
exercise trials.
Exercise log data
The exercise training records provided information related
to the volume of resistance training performed during the
seven day supplementation period. Subjects were asked to
record the number of sets and repetitions performed for
each training exercise per session. Resistance training
movements were classified, by investigators, based on
upper versus lower extremity movements and based on
compound versus single-joint exercises, thus establishing
four exercise categories: upper extremity compound,
upper extremity single-joint, lower extremity compound,
and lower extremity single-joint. Table 2 provides a com-
parison of the training volume between placebo and
GPLC conditions relative to the exercise categories. Analy-
ses revealed no significant differences in the number of
sets or repetitions between conditions in any of the four
exercise categories (p > 0.05).
Power Output
The three measures of power output (PP, MP, and DEC)
were found to vary significantly with bout order (p <
0.001). In the case of PP and MP, values decreased while
DEC increased with subsequent sprint bouts. Mean values
of PP, MP, and DEC across the five sprint bouts are pre-
sented graphically in Figures 1, 2 and 3, respectively. Fig-
ures 4 and 5 depict the HR and LAC responses across the
five sprint bouts, again values increasing with the subse-
quent bouts.
Peak Power
Supplementation of GPLC had a significant main effect
on PP (p < 0.05). Across the five sprint bouts, PP was
1.7%, 0.2%, 4.1%, 15.7%, and 4.4% greater with GPLC.
There was also a significant interaction between GPLC
Table 1: Nutritional recall information placebo GPLC
Placebo GPLC
Protein (gr) 179.8 ± 74.6 184.9 ± 75.7
% total cals 29% 30%
Carbohydrates (gr) 272.6 ± 145.1 254.4 ± 130.0
% total cals 44% 42%
Fats (gr) 73.8 ± 30.2 75.7 ± 32.6
% total cals 27% 28%
Total Calories 2482.2 ± 739.9 2434.1 ± 761.0Journal of the International Society of Sports Nutrition 2009, 6:9 http://www.jissn.com/content/6/1/9
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and sprint bouts on PP. Analysis revealed that values of PP
for bouts three, four and five were statistically greater (p's
< 0.05) with GPLC.
Mean Power
There wasn't a statistically significant effect of GPLC on
MP (p = 0.083). Mean values of MP were 2 – 24% greater
with GPLC across sprint bouts one through five. A signifi-
cant interaction was detected between GPLC and sprint
bouts (p < 0.01). Post hoc one-way ANOVA for repeated
measures showed MP produced during sprints four and
five with GPLC were significantly greater than the values
produced with PL (p's < 0.05).
Power Decrement
Figure 3 displays the DEC values during both test condi-
tions. As previously mentioned, DEC increased signifi-
cantly with ongoing sprint bouts. However, analysis of the
DEC data did not reveal significant effects of GPLC (p =
0.65) or significant interaction with sprint bouts (p =
0.51). Interestingly, the difference between conditions in
mean values of DEC tended to increase as sprint bouts
progressed with a statistically significant difference (p <
0.05) in the fifth sprint with a 38% power decrement with
PL while GPLC produced a 41.3% rate of power decre-
ment.
Relative total power decrement within each test session
for PP was lower with GPLC than PL, with 26.6% and
32.8% declines in those values respectively, however this
difference was not statistically significant (p = 0.09). The
mean MP total power decrement values were not statisti-
cally different between groups (p = 0.32) with 36.4% and
33.1% for GPLC and PL, respectively.
Lactate
A significant main effect for condition was observed for
lactate measures (p < 0.05). Figure 4 displays the lactate
measures at rest as well as four and 14 minutes post-exer-
cise. There were no significant differences between condi-
tions in lactate levels at rest. Lactate measures taken at four
and fourteen minutes post-exercise were 15.6% and
16.2% lower, respectively, with GPLC. Paired timepoint
analyses indicated that the differences between conditions
were statistically significant at 14 minutes post-exercise (p
< 0.05) but not four minutes following the sprint bouts (p
= 0.09). Net lactate accumulation per unit power output,
calculated as (LAC14-LACrest).  (MPave)-1  differed signifi-
cantly between conditions (p < 0.05). GPLC produced
22.8% less net lactate per watt than placebo, 0.947 and
1.227 mmol. watt-1, respectively
Heart rate
Heart rate was recorded at rest, during the final 10 seconds
of each sprint bout, as well as 4 and 14 minutes post-exer-
cise (see Figure 5). There were no significant effects of con-
dition or interaction effects detected for values of HR. As
previously mentioned, HR tended to increase across time
with a considerable increase in HR from rest to bout 1,
then slightly increasing with subsequent sprint bouts to
peak values of approximately 169 bpm in both condi-
tions. Post-exercise HR responses did not differ apprecia-
bly between the GPLC and PL conditions with values of
approximately 130 and 111 bpm at four and 14 minutes,
respectively, following the sprints.
Thigh girth
There were no significant main condition effects or condi-
tion × time interactions in the measures of thigh girth.
There was a significant main effect of time (pre-, post-exer-
cise) indicating similar increases in thigh girth in both
conditions (GPLC, PL). Girth increased from 57.1 ± 6.0 to
58.9 ± 6.1 cm for the PL condition with the GPLC condi-
tion producing a slightly greater (5%) expansion of thigh
circumference from 57.3 ± 6.4 cm at rest to 59.1 ± 6.3 cm
four min after exercise.
Discussion
The findings of this study demonstrate that short-term
GPLC supplementation may significantly enhance anaer-
obic work capacity in resistance trained males. These find-
ings are particularly striking when considered in
combination with the significant reduction in lactate
accumulation following GPLC supplementation. A post-
hoc analysis revealed a 22.8% reduction in the ratio of net
lactate accumulation per unit of power output. The effects
documented in this investigation generally exceed those
of previous studies investigating L-carnitine supplementa-
Table 2: Exercise training volume placebo GPLC
Placebo GPLC
Upper Extremity Sets 38.5 ± 16.8 37.9 ± 17.8
Compound Exercises Reps 383.0 ± 199.3 470.0 ± 371.9
Upper Extremity Sets 34.0 ± 21.7 36.3 ± 24.7
Single Joint Exercises Reps 414.6 ± 262.8 470.0 ± 371.9
Lower Extremity Sets 9.7 ± 5.8 8.0 ± 5.9
Compound Exercises Reps 81.5 ± 57.5 92.4 ± 127.1
Lower Extremity Sets 10.0 ± 7.4 9.6 ± 9.0
Single Joint Exercises Reps 111.2 ± 90.8 159.8 ± 260.8Journal of the International Society of Sports Nutrition 2009, 6:9 http://www.jissn.com/content/6/1/9
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tion and exercise performance. In order to discuss the
findings of the present study in reference to previous
work, it is useful to first consider the known metabolic
functions of carnitine and its acyl variations.
Carnitine is endogenously metabolized and obtained
from dietary sources such as meat and dairy products.
Over 80% of carnitine is found in skeletal muscle tissue
where it fulfils two vital metabolic functions. Both func-
tions involve the exchange of activated acyl carboxylic
acids (acyl groups) between carnitine and Coenzyme A.
The total carnitine pool is composed of free carnitine and
acylcarntines (both long chain and short chain) and the
balance between free carnitine and the acyl variations is
an indication of metabolic activity and exercise intensity.
The metabolic function commonly associated with carni-
tine is the shuttling of free fatty acids (long chain acyl-
CoAs) into the inner region of the mitochonia where beta
oxidation of the acyl groups takes place. The carnitine
pool provides a vital role in this process as the long chain
fatty acyl-CoAs are actually unable to enter the inner mito-
chondrial matrix due to their large size. Acyl groups are
exchanged between free carnitine and acylcarnitine,
which is readily able to travel into the inner matrix where
the acyl-CoA is reformed using the reverse mechanism.
The process of conversion between free carnitine and acyl-
carnitines is dependent on three carnitine enzymes. Car-
nitine Palmitoyltransferase (CPT1) activates the
conversion of carnitine and long chain acyl-CoAs to form
long chain acetylcarnitine (most often acetylcarnitine)
and Coenzyme A which can effectively pass into the inner
regions of the mitochondia. CPT1 activity is based on ade-
quate muscle levels of carnitine, which progressively
declines with increased production of acetylcarnitines as
exercise intensity and/or duration increases. Thus, CPT1 is
considered the rate limiting enzyme of oxidation of long
chain fatty CoAs with muscle carnitine levels actually serv-
ing as a control mechanism of this metabolic pathway.
The association of muscle carnitine levels and acyl-CoA
oxidation is the basis of a multi-million energy and
weight loss nutraceutical industry.
Carnitine serves a second critical metabolic function, buff-
ering the Coenzyme A pool against accumulation of short
chain acetyl-CoAs, which at increasing levels reduce the
activity of the pyuvate dehydrogenase complex (PDC).
Increased levels of acetyl-CoAs inhibit PDC activity
thereby reducing the ability to produce a substrate capable
of entering the citric acid cycle thereby resulting in
increased lactate production. The shift from short chain
acetyl-CoA to lactate production is considered an indica-
tion that anaerobic processes exceed the capability of the
citric acid cycle. In the setting of increased short chain
acetyl-CoAs, carnitine is capable of accepting the acyl
group in the development of acylcarnitine (generally ace-
tylcarnitine) effectively reducing the level of acetyl-CoA
and extending the ability to continue high intensity exer-
cise. This process is limited by the muscle carnitine levels
which are gradually reduced with continued intense exer-
cise. Thus, muscle carnitine levels have been associated
with the ability to sustain high anaerobic efforts with
reduced output of lactate. Another multi-million dollar
industry, based on enhancement of sports performance, is
predicated on these anaerobic buffering processes and the
role of carnitine.
Investigations of the effects of L-carnitine supplementa-
tion and exercise performance have yielded equivocal
findings which have been carefully discussed in several
published reviews [9,14,15]. The majority of exercise trials
examining the efficacy of L-carnitine have based their
work on the role of carnitine in the transport of fatty acids
and therefore used endurance performance protocols with
outcomes measures including maximal oxygen uptake
(VO2 max) or markers of anaerobic threshold as deter-
mined during graded incremental exercise testing. In gen-
eral, most studies have failed to document increases in
VO2 max or performance markers whether examining
untrained or athletic persons. The authors of those indi-
vidual studies as well as the reviewers have generally
attributed the lack of performance benefits with L-carni-
tine to the inability to increase resting muscle carnitine
Carnitine+acyl-CoA acylcarnitine+Coenzyme A ⇔
Peak power (PP) determined during repeated cycling sprints  with Placebo (dotted columns) and with GPLC (darkened  columns) Figure 1
Peak power (PP) determined during repeated cycling 
sprints with Placebo (dotted columns) and with 
GPLC (darkened columns). Note: Significant condition 
main effect (p < 0.01) and interaction effect (p < 0.05). Signif-
icant paired time contrasts for sprints 3, 4, and 5 (p < 0.05). 
Values are mean ± SD. * denotes statistically significant differ-
ence between conditions (p < 0.05)
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concentrations. However, several studies have reported
increased VO2 max [12,16,17] and/or reduced post-exercise
lactate accumulation [17,18]. While there have been pos-
itive reports of carnitine supplementation and enhanced
exercise performance and/or improved responses to exer-
cise, there has been a general consensus to disregard the
validity of those findings as the predominate opinion is
that any performance enhancements must be predicated
on increased resting muscle carnitine levels. Thus, there
has been a general reconsideration of carnitine supple-
mentation has a means not to improve exercise perform-
ance but rather to enhance recovery from hypoxic stresses
associated with exercise [19,20].
Recently, it has been shown that muscle carnitine content
can be increased via an interesting approach. Stephens
and associates [21] reported that infusion of a physiolog-
ically high level of insulin concurrent with infusion of car-
nitine significantly elevated the muscle carnitine
concentrations in eight healthy men. Moreover using the
same hyperinsulinemia strategy, that research group also
documented reduced PDC activity and muscle lactate lev-
els with increased muscle glycogen stores presumably
related to increased muscle carnitine levels following IV
infusion of insulin and carnitine [22]. These findings are
clear evidence that it is possible to increase muscle carni-
tine levels, in this case via the influences of high insulin
levels. It is well established that insulin itself acts as a reg-
ulator for vasodilation and blood flow by modulating
nitric oxide synthesis and release [23]. Thus, it is possible
that the increase in muscle carnitine levels were increased
to a great extent due to NO providing vasodilation and
enhanced capillary filling, which provides direct muscle
access to the elevated plasma concentration of carnitine.
Stephens et al. [21,22] suggested their findings may pro-
vide insight into persons with diabetes and obesity where
fat oxidation processes are limited, it is doubtful this
approach would be beneficial in those clinical popula-
tions. Rather, those clinical conditions are commonly
associated with varying states of insulin resistance which
would likely limit the effectiveness of this carnitine load-
ing strategy.
The research of Arenas et al. [24,25] and Huertes et al. [26]
provides an alternative perspective to the application of
carnitine loading for supraphysiological resting concen-
trations. Those researchers examined the application of L-
carnitine (1–2 grams daily) in long distance runners and
sprinters over one to six month periods of training. They
documented reductions in free carnitine with intense
training in agreement with the previous work of other
researchers but provided the unique finding that carnitine
supplementation alleviated all training induced deficits in
total and free carnitine. Increased activity of respiratory
chain enzymes and PDH activity were associated with
increased VO2 max in the supplemented athletes. Thus,
these findings would suggest that chronic carnitine
administration may replenish gradual chronic reductions
in resting muscle carnitine levels, as developed with ongo-
ing stressful exercise training. In this way it is not neces-
sary to attain considerably increased levels of muscle
carnitine to effectively enhance performance, but rather
prevent deleterious reductions in those concentrations. A
means to apply this approach to high intensity exercise,
where reduced free carnitine supply is associated with
anaerobic work capacity and resistance to local muscle
fatigue, would provide benefits to many different popula-
tions ranging from clinical populations with neuromus-
cular disorders to elite athletic competitors.
The acylcarnitine pool includes the previously mentioned
acetylcarnitine and propionylcarnitine (PC), which is
metabolized by carnitine acetyltransferase from propio-
nyl-CoA. Propionylcarnitine possesses three characteris-
tics that distinguish this acylcarnitine from other
members of the carnitine pool. First, it has a unique
vasodilatory effect which is specific to this compound.
This may be the reason that PC has been shown to have a
high affinity for both skeletal and cardiac muscle tissue.
Secondly, PC provides a source of propionyl units which
are easily transformed into succinate for mitochondrial
utilization in the citric acid cycle as a source of anaplerotic
energy. In this way, PC supplies an active energy substrate
even during periods of limitations in localized oxygen
availability, ie muscle ischemia. Finally, PC provides a
replenishment of free carnitine in cases of deficiency with
Mean power (MP) determined during repeated cycling sprints  with Placebo (dotted columns) and with GPLC (darkened  columns) Figure 2
Mean power (MP) determined during repeated 
cycling sprints with Placebo (dotted columns) and 
with GPLC (darkened columns). Note: Significant inter-
action effect (p < 0.05). Significant paired time contrasts for 
sprints 4 and 5 (p < 0.05). Values are mean ± SD. * denotes 
statistically significant difference between conditions (p < 
0.05)
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intense exercise or disease. Propionyl-L-carnitine, being a
prescription medication in both Europe and the United
States, has been examined primarily as a treatment in clin-
ical populations with apparent muscle carnitine deficien-
cies. Controlled clinical trials indicated that PLC provides
enhanced work capacity in persons with congestive heart
failure [27] and peripheral vascular disease [28].
Glycine propionyl-L-carnitine (GPLC) is a novel nutrient
consisting of a molecularly bonded combination of PLC
and the amino acid glycine. Glycine is considered as a glu-
cogenic amino acid in that it helps to regulate blood sugar
levels and is also very important in the formation of crea-
tine. Interestingly, glycine has been shown to have its own
independent vasodilatory effects [29]. Limited research
has examined the effects of GPLC on exercise performance
within the general population or athletes. An ishchemic-
reperfusion model was used by Bloomer, Smith, and
Fisher-Wellman to examine blood nitrite/nitrate levels as
an indication of NO production [13]. This model pro-
vides a means to assess physiological measures such as
blood flow and increased levels of NO in response to
occlusive stresses similar to those exhibited during high
intensity resistance training. Those studies indicated that
GPLC supplementation at 4.5 g per day for one week pro-
duced dramatically greater blood nitrite/nitrate levels
both at rest and in response to the occlusion/reperfusion
stress. Those findings are particularly notable as GPLC is
the first and only nutritional supplement product proven
to increase NO synthesis. Smith and associates [30]
reported findings related to a group of previously inactive
persons, who for eight weeks performed stationary cycling
and/or walking with GPLC supplementation. Study par-
ticipants were randomized to receive placebo, 1 or 3 g
GPLC per day. The exercise testing, performed prior to and
following the eight weeks of training, consisted of the
standard Bruce protocol treadmill test and standard 30 sec
Wingate test. Thus, the testing procedures introduced a
high degree of variability which may have limited measur-
able performance effects with GPLC. However, there was
a significant treatment main effect with the GPLC 1 g/day
group displaying a greater lactate threshold than the pla-
cebo group (64.5% vs 56. 0% VO2 max). There was also a
statistically non-significant trend (p = 0.09) for greater rel-
ative change in lactate threshold in both GPLC groups (1
g, 10.3%; 3 g, 8.8%) compared with the placebo group
(3.5%). There was no difference in muscle carnitine meas-
ures between study groups following eight weeks of sup-
plementation.
The results of the present investigation do not directly
conflict with the findings of the Webb et al. study. The
testing protocol used in the present study differed sub-
stantially from the graded incremental treadmill protocol
used in the Webb report. However, an increased work
capacity to lactate threshold was associated with GPLC in
those treadmill assessments. The reported lack of anaero-
bic benefits of GPLC in the Webb study was based on per-
formance of a single 30-sec Wingate sprint. The present
investigation applied repeated 10-sec sprints, and found
no significant differences between groups in the first two
sprints. It was only during the third, fourth, and fifth
sprints that the GPLC condition produced significantly
more power output and with less lactate accumulation.
It is possible to establish a plausible mechanistic explana-
tion using 1) the performance outcomes of the present
investigation in combination with 2) previously estab-
lished mechanisms of the underlying carnitine molecules,
and 3) recent reports of increased muscle carnitine levels
via insulin infusion. The authors of the present study pro-
pose that GPLC provides theoretical advantages by way of
replenishment of carnitine stores which generally decline
during stressful exercise and the inclusion of an additional
energy source, via characteristics that are unique to this
molecularly bonded form of carnitine. First, the vasodila-
tory effects associated with increased NO are seen as the
critical action responsible for these impressive findings.
Prior studies have generally indicated that L-carnitine
does not provide performance benefits, which usually was
attributed to the inability to significantly increase resting
muscle carnitine concentrations. The exception to that
rule has been with increased insulin levels which are
known to modulate the NO pathway. It is proposed that
GPLC provides a means to elevate blood flow during vig-
orous exercise via increased production of NO. Reduced
vasotension and relaxed capillary sphincters allow consid-
Decrement in power output (DEC) determined during  repeated cycling sprints with Placebo (dotted columns) and  with GPLC (darkened columns) Figure 3
Decrement in power output (DEC) determined dur-
ing repeated cycling sprints with Placebo (dotted col-
umns) and with GPLC (darkened columns). Note: No 
significant main condition or interaction effects (p > 0.05). 
Significant paired time contrast for sprint 5 (p < 0.05). Values 
are mean ± SD
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erably elevated local blood flow into the capillary bed
thereby providing an enhanced exchange of nutrients and
metabolic products. The walls of capillaries are composed
of a single layer of endothelium cells without the smooth
musculature found in terminal arterioles. Capillaries are
surrounded by several muscle fibers within the same
motor unit thereby providing direct interface with the
blood system and the nutrients it carries.
Within the muscle tissue, the supplemented acylcarnti-
tines are converted to free carnitine and propinyl-CoA.
Propionate serves as an anaplerotic energy substrate even
in the environment of muscle ischemia evident with
intense muscular exertion or disease states. Free carnitine
is also produced via this mechanism thereby replenishing,
to some degree, muscle carnitine levels that tend to
decline with increasing conversion to long chain acylcar-
nitines during transport of acyl-CoAs into the mitochon-
drial matrix. Deficits in carnitine stores exhibited during
high intensity anaerobic work may be reduced as replen-
ishing free carnitine levels facilitates the production of
short chain acylcarnitines as a buffering process that
reduces lactate accumulation. This model may provide
enhanced fatty acid oxidation at rest and during submax-
imal exercise to the point of lactate threshold. Comple-
mentary anaerobic benefits are provided with high
intensity exercise via enhanced blood flow related to
increased NO synthesis, the addition of an anaplerotic
energy source in propionate. Anaerobic power is
enhanced by buffering Coenzyme A by carnitine thereby
preventing the elevation of Acetyl-CoA levels which
would generally hinder the activity of the PDC thereby
stimulating the production of lactate. Thus, at rest and
during moderate intensity exercise GPLC appears to
enhance fatty acid oxidation and aerobic metabolism
while it increases anaerobic power with reduced lactate
production during high intensity exercise.
This simplistic mechanistic model is based on numerous
previously established functions of the total carnitine
pool, in conjunction with the unique characteristics of
GPLC as reported in recent investigations, as well as from
the present study. The 4.5 gram dosage of GPLC used in
this study was similar to that applied by Bloomer [13], but
that study applied the daily dose over a one week period.
Furthermore, the present study did not measure NOx,
thus it is not possible to establish the role of NO in the
findings of the present study. In fact, the only means of
assessing reactive hyperemia of the lower extremities in
the present study was the thigh girth as determined using
a basic Gulick measuring tape. Based on the magnitude of
NOx increases reported by Bloomer's group, it was
hypothesized that GPLC may produce increases in local
blood flow which might be measurable using a basic girth
assessment. However, the increase in thigh girth was not
significantly different between study conditions. Thus, it
is uncertain whether the performance benefits observed in
the present study were related to increased levels of NO or
other mechanisms of action. Certainly, the present inves-
tigation should be replicated, with examination of varying
dosages over extended periods of time, with valid out-
come measures that indicate critical metabolic pathway
activity. The present study is seen as proof of concept that
oral GPLC administration can increase peak anaerobic
power output with reduced lactate accumulation.
Conclusion
In conclusion, the findings of the present investigation
demonstrate that short-term supplementation of GPLC
produces significant enhancement of anaerobic power
during repeated cycle sprints in resistance trained men.
The increase in peak power output was accompanied by a
significantly lower accumulation of lactate. These findings
provide the first evidence that the previously observed
increases in NO with GPLC may be associated with per-
formance improvements in trained individuals. While the
present findings should be limited at this time to the
resistance trained male population under direct examina-
tion, these results suggest application in various groups
that exhibit reduced muscle carnitine content and the
associated limitations in physical performance.
A simple theoretical model of GPLC and altered meta-
bolic activity has been presented. These authors suggest
that the vasodilatory effects of GPLC, presumably associ-
ated with increased NO synthesis, allow an effective inter-
Lactate (PP) assessed during at rest and 4 min and 14 min fol- lowing repeated cycling sprints with Placebo (dotted col- umns) and with GPLC (darkened columns) Figure 4
Lactate (PP) assessed during at rest and 4 min and 14 
min following repeated cycling sprints with Placebo 
(dotted columns) and with GPLC (darkened col-
umns). Note: Significant condition main effect (p < 0.05). 
Significant paired time contrast for 14 min post sprints (p < 
0.05) but not 4 min post sprint (p = 0.09). * denotes statisti-
cally significant difference between conditions (p < 0.05)
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face between muscle tissue and the blood stream as the
capillary bed progressively engorges during high intensity
exercise. Thus, a paradigm shift from the conventional
approach of nutritional supplementation has been estab-
lished. It has been generally assumed that resting nutrient
stores must be significantly increased in order to produce
performance enhancements. It is suggested that, in some
situations, certain nutrients that are utilized in the meta-
bolic activities of high intensity exercise may be effectively
restored via diffusion from higher concentrations of that
nutrient within the blood serum. The effectiveness of this
general strategy has been demonstrated previously with
different micronutrients via infusion of insulin and inges-
tion of high glycemic index carbohydrate foods to induce
spikes of insulin. This is, to some degree, the very basis of
various nutrient timing strategies commonly applied in
athletic training. It appears that GPLC, in conjunction
with high intensity exercise, has the capacity to effectively
enhance the uptake of certain micronutrients into muscle
tissue thereby providing a viable alternative for the low-
carbohydrate lifestyle and for persons with reduced insu-
lin sensitivity.
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